Proton vs Photon IMRT Toxicity in Breast Cancer (NCT07537712) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Proton vs Photon IMRT Toxicity in Breast Cancer
China750 participantsStarted 2026-04
Plain-language summary
This study aims to compare the differences in acute and long-term toxicities between intensity-modulated proton therapy (IMPT) and intensity-modulated photon radiotherapy (IMRT/VMAT) in postoperative breast cancer patients, with a focus on evaluating their impact on critical organs, including the heart, lungs, skin, esophagus, thyroid, and lymphatic tissues. Eligible patients will be followed for at least one year to assess the incidence and severity of both acute and late toxicities, as well as differences in patient-reported outcomes (PROs), cosmetic outcomes following breast-conserving surgery, and overall quality of life.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Female patients aged ≥18 years.
✓. Pathological diagnosis of invasive breast cancer or ductal carcinoma in situ.
✓. Undergone breast-conserving surgery or total mastectomy, with or without stage I breast reconstruction.
✓. For invasive carcinoma, sentinel lymph node biopsy, axillary lymph node sampling, or axillary lymph node dissection was performed.